论文部分内容阅读
间充质干细胞(mesenchymal stemcells,MSCs)的分化潜能及免疫抑制能力的发现和相关研究的进展,使其有望应用于临床治疗退行性疾病和免疫失调症。MSCs发挥免疫抑制作用时,先通过免疫激活的T细胞释放IFNγ、TNFα和IL-1等细胞因子,进而刺激MSCs产生大量不同趋化因子和一氧化氮(nitricoxide,NO);趋化因子招募T细胞向MSCs聚集,MSCs生成的NO抑制T细胞增殖,产生免疫抑制效果。相关研究进展为MSCs有效应用于移植物抗宿主病(graft versus host disease,GVHD)等临床免疫性疾病治疗提供了理论指导,并展现出极大的应用前景。
The differentiation potential of mesenchymal stem cells (MSCs) and the development of immunosuppressive ability and their related research are expected to be used clinically in the treatment of degenerative diseases and immune disorders. MSCs play an immunosuppressive role, first by immune activation of T cells release of IFNγ, TNFα and IL-1 and other cytokines, thereby stimulating MSCs produce a large number of different chemokines and nitric oxide (NO); chemokine recruitment T Cells to MSCs gathered MSCs generated by the inhibition of T cell proliferation, resulting in immunosuppressive effect. The related research has provided theoretical guidance for the MSCs to be effectively used in the treatment of clinically immune diseases such as graft versus host disease (GVHD), and has shown great application prospect.